WA-SPIE
29.1.2024 20:25:27 CET | Business Wire | Press release
SPIE, the international society for optics and photonics, and The University of Manchester announced the establishment of the SPIE-Manchester Postgraduate Scholarship in Photonics, today during SPIE Photonics West in San Francisco. The $500,000 gift from SPIE will be matched 100% by the University. Part of the SPIE Endowment Matching Program, this new endowment will support both early-career researchers and returning researchers at the University’s Photon Science Institute in partnership with the Royce Institute, the UK’s national institute for advanced materials research and innovation. This is the 11th major SPIE gift to universities and institutes as part of the Society's ongoing program to support the expansion of optical engineering teaching and research.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240126857659/en/
Doctoral students at work in the Photon Science Institute lab. (Photo: Business Wire)
With a goal of increasing diversity in optics and photonics, the SPIE-Manchester Postgraduate Scholarship will have a particular focus on funding individuals returning to research following a career break or time in industry, and those pursuing unconventional career pathways or part-time study (situations often necessitated by caring responsibilities, for example). Aligning current research and industrial needs for a robust training pipeline, an additional unique feature of the scholarship is an optional final-year placement of up to 12 months, during which students can develop industry-relevant skills in collaboration with local optics and photonics companies.
“Today marks just the beginning of the partnership between The University of Manchester and SPIE,” noted Department Head of Research for Physics and Astronomy at The University of Manchester Dr. Patrick Parkinson. “The establishment of the SPIE-Manchester Postgraduate Scholarship in Photonics is a testament to our shared values within skills training, fostering diversity in education and the vital role of photonics. This announcement holds special significance as it coincides with the University’s bicentenary year. We take great pride in using this generous donation to not only advance research and education, but also to solidify our existing partnerships and forge new industrial collaborations to deliver a doctoral training program that will ensure a sustainable workforce for the North West of England.”
“Our expanding field needs researchers and engineers, though for some who might be interested in a photonics career, traditional educational paths are barriers to their success,” said SPIE CEO Kent Rochford. “The SPIE-Manchester Postgraduate Scholarship in Photonics aims to remove those barriers and provide exciting opportunities for early-career researchers and those who may be pursuing unconventional career paths. Working internally at the university’s Photon Science Institute with the option of an industry-focused placement, promises to benefit young researchers, as well as our future diverse workforce. I very much look forward to meeting the leaders in optics and photonics technologies who will emerge from this dynamic partnership between SPIE and The University of Manchester.”
The SPIE Endowment Matching Program was established in 2019 to increase international capacity in the teaching and research of optics and photonics. With this latest gift, SPIE has provided over $4 million in matching gifts, resulting in more than $11 million in dedicated funds. The SPIE Endowment Matching Program supports optics and photonics education and the future of the industry by contributing a match of up to $500,000 per award to college, institute, and university programs with optics and photonics degrees, or with other disciplines allied to the SPIE mission.
About the University of Manchester
The University of Manchester is a member of the prestigious Russell Group and one of the UK’s largest single-site universities. We have over 40,000 students, 12,000 staff and, with 500,000 former students from more than 190 countries, are home to the largest alumni community of any campus-based university in the UK. We are ranked in the top ten of the Times Higher Education (THE) Impact Rankings globally; are the top UK University for graduate employability according to The Graduate Market in 2022 and no fewer than 25 Nobel laureates have either worked or studied here. Manchester was also named 5th place for research power — the quality and scale of research and impact — in the UK government’s (REF) 2021. Visit www.manchester.ac.uk for further information or https://www.manchester.ac.uk/discover/vision/ for our latest strategic vision.
About SPIE
SPIE, the international society for optics and photonics, brings engineers, scientists, students, and business professionals together to advance light-based science and technology. The Society, founded in 1955, connects and engages with our global constituency through industry-leading conferences and exhibitions; publications of conference proceedings, books, and journals in the SPIE Digital Library; and career-building opportunities. Over the past five years, SPIE has contributed more than $24 million to the international optics community through our advocacy and support, including scholarships, educational resources, travel grants, endowed gifts, and public-policy development. www.spie.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240126857659/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom